Product Overview
Our OsteoSurge® 300 grafts combine demineralized bone matrix with patented Accell® bone matrix in a bioresorbable, reverse phase medium carrier. Provided in an open-bore syringe, the putty is moldable and resists irrigation.
Key Features:
• Accell Technology - The patented Accell process yields Accell bone matrix (ABM). ABM is an open-structured, dispersed form of DBM. OsteoSurge 300 and OsteoSurge 300c DBM contain the highest concentration of ABM available in our products.
• Superior Handling - The unique, poloxamer, reverse phase medium carrier, which becomes more viscous at body temperature, provides exceptional handling and containment characteristics. The graft is moldable, packable, mixable and resists irrigation.
• Verified Osteoinductive Potential - Every lot of DBM is tested in a validated, in vitro assay to verify osteoinductive potential.
• Expert Processing - Cortical bone and cancellous bone obtained from AATB-accredited tissue banks is processed into DBM in our state-of-the-art facility. The demineralization process is tightly controlled to consistently produce demineralized bone.
• Electron Beam Sterilization - The processing of DBM and ABM is completed under aseptic conditions in our state-of-the-art facility. As the last step in manufacturing, the graft is sterilized via electron beam irradiation.
Indications:
OsteoSurge® 300 Demineralized Bone Matrix is intended for filling voids and gaps in the skeletal system that are not intrinsic to the stability of the bony structure. OsteoSurge 300 is indicated for use as a bone graft extender in the spine, extremities and pelvis. OsteoSurge 300 may also be used as a bone void filler in the posterolateral spine, extremities and pelvis. The voids or gaps may be surgically created defects or the result of traumatic injury to the bone. (https://www.seaspine.com/)
